OKYO announces the appointment of Dr Rajkumar Patil as Chief Scientific Officer
OKYO announces the appointment of Dr Rajkumar Patil as Chief Scientific Officer
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, announces that it has CE-Marked Mologic Ltd’s (‘Mologic’) lateral flow antigen test for COVID-19, to
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, announces that a UK Public Sector contract disclosure has been published yesterday in relation to
Contract with Screen4 for COVID-19 antibody laboratory-based testing service
Lateral flow test data shows potential for companion diagnostic to the Pfizer-BioNTech COVID-19 vaccine
OKYO Pharma has U.S. Patent Issued Covering its Lipid Conjugated Peptide Analogues for treating Ocular Pain and Inflammation
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes
Director/PDMR Shareholding – Exercise of Options and Total Voting Rights
UK Government manufacturing contract Board appointment & trading update
Update re AbC-19TM Rapid TestÂ
OKYO announces filing of a patent application covering the use of Chemerin and associated analogues to treat “cytokine storm” associated with COVID-19 and ARDS